Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorGUIMARAES, Elizandra Silva
dc.contributor.authorCERDA, Alvaro
dc.contributor.authorDOREA, Egidio Lima
dc.contributor.authorBERNIK, Marcia Martins Silveira
dc.contributor.authorGUSUKUMA, Maria Cecilia
dc.contributor.authorPINTO, Gelba Almeida
dc.contributor.authorFAJARDO, Cristina Moreno
dc.contributor.authorHIRATA, Mario Hiroyuki
dc.contributor.authorHIRATA, Rosario Dominguez Crespo
dc.date.accessioned2017-12-12T13:27:13Z
dc.date.available2017-12-12T13:27:13Z
dc.date.issued2017
dc.description.abstractAimThe influence of short-term add-on ezetimibe to simvastatin treatment on expression of adipokines and inflammatory markers was investigated in diabetic and nondiabetic patients with hypercholesterolemia. MethodHypercholesterolemic nondiabetic (HC, n=37) and diabetic (DM, n=47) patients were treated with simvastatin (SV, 10 or 20mg/d/8-wk) and then SV plus ezetimibe (SV+EZ, 10mg each/d/4wk). Serum lipids, glycemic profile, and inflammatory markers (hsCRP, adiponectin, resistin, VCAM-1, and ICAM-1) were evaluated before and after the add-on ezetimibe therapy. mRNA expression of ADIPOR1, ADIPOR2, RETN, VCAM1, and ICAM1 was measured by real-time PCR in peripheral blood mononuclear cells (PBMC). ResultsSerum concentrations of LDL and HDL cholesterol, and adiponectin were higher in HC than DM patients (P<.05). The add-on ezetimibe therapy reduced total and LDL cholesterol, apoB and adiponectin serum levels in HC and DM groups, and resistin in HC subjects (P<.05). DM patients showed higher expression of ADIPOR1, ADIPOR2, RETN, and VCAM1 in PBMC than subjects in HC group, before and after add-on ezetimibe therapy (P<.05). PBMC RETNmRNA expression was reduced by add-on ezetimibe therapy in HC individuals (P<.05), but not in DM subjects. ConclusionShort-term add-on ezetimibe to simvastatin treatment suppressing effects on hypercholesterolemia and adiponectinemia is independent of the diabetes status. Resistin serum levels and leukocyte mRNA expression are influenced by add-on ezetimibe to statin treatment.
dc.description.indexMEDLINE
dc.description.sponsorshipFAPESP, Sao Paulo, Brazil [2010/15353-8]
dc.description.sponsorshipCNPq, Brazil
dc.identifier.citationCARDIOVASCULAR THERAPEUTICS, v.35, n.6, article ID UNSP e12307, 8p, 2017
dc.identifier.doi10.1111/1755-5922.12307
dc.identifier.eissn1755-5922
dc.identifier.issn1755-5914
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/24511
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofCardiovascular Therapeutics
dc.rightsrestrictedAccess
dc.rights.holderCopyright WILEY
dc.subjectAdipokines
dc.subjectDiabetes
dc.subjectDyslipidemia
dc.subjectEzetimibe
dc.subjectInflammatory markers
dc.subjectmRNA expression
dc.subjectStatin
dc.subject.othercoronary-artery-disease
dc.subject.othercardiovascular-disease
dc.subject.othercombination therapy
dc.subject.otherisolated hypercholesterolemia
dc.subject.otherendothelial dysfunction
dc.subject.othercholesterol absorption
dc.subject.otherinsulin sensitivity
dc.subject.othermetabolic syndrome
dc.subject.othersimvastatin
dc.subject.otherresistin
dc.subject.wosCardiac & Cardiovascular Systems
dc.subject.wosPharmacology & Pharmacy
dc.titleEffects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryChile
hcfmusp.affiliation.countryisocl
hcfmusp.author.externalGUIMARAES, Elizandra Silva:Univ Sao Paulo, Dept Clin & Toxicol Anal, Sch Pharmaceut Sci, Sao Paulo, Brazil
hcfmusp.author.externalCERDA, Alvaro:Univ La Frontera, CETM BIOREN, Ctr Excellence Translat Med, Dept Basic Sci, Temuco, Chile
hcfmusp.author.externalBERNIK, Marcia Martins Silveira:Univ Sao Paulo, Univ Hosp, Sao Paulo, Brazil
hcfmusp.author.externalFAJARDO, Cristina Moreno:Univ Sao Paulo, Dept Clin & Toxicol Anal, Sch Pharmaceut Sci, Sao Paulo, Brazil
hcfmusp.author.externalHIRATA, Mario Hiroyuki:Univ Sao Paulo, Dept Clin & Toxicol Anal, Sch Pharmaceut Sci, Sao Paulo, Brazil
hcfmusp.author.externalHIRATA, Rosario Dominguez Crespo:Univ Sao Paulo, Dept Clin & Toxicol Anal, Sch Pharmaceut Sci, Sao Paulo, Brazil
hcfmusp.citation.scopus6
hcfmusp.contributor.author-fmusphcEGIDIO LIMA DOREA
hcfmusp.contributor.author-fmusphcMARIA CECILIA GUSUKUMA
hcfmusp.contributor.author-fmusphcGELBA ALMEIDA PINTO
hcfmusp.description.articlenumberUNSP e12307
hcfmusp.description.issue6
hcfmusp.description.volume35
hcfmusp.origemWOS
hcfmusp.origem.pubmed28940978
hcfmusp.origem.scopus2-s2.0-85033455407
hcfmusp.origem.wosWOS:000414962500014
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceArsenault BJ, 2016, AM J CARDIOL, V118, P494, DOI 10.1016/j.amjcard.2016.05.044
hcfmusp.relation.referenceCerda A, 2015, CARDIOVASC THER, V33, P168, DOI 10.1111/1755-5922.12126
hcfmusp.relation.referenceKater ALD, 2010, METABOLISM, V59, P921, DOI 10.1016/j.metabol.2010.02.011
hcfmusp.relation.referenceDerosa G, 2016, VASC HEALTH RISK MAN, V12, P415, DOI 10.2147/VHRM.S64460
hcfmusp.relation.referenceDolezelova E, 2017, BRIT J CLIN PHARMACO, V83, P1380, DOI 10.1111/bcp.13250
hcfmusp.relation.referenceFederici M, 2015, ATHEROSCLEROSIS SUPP, V17, P17, DOI 10.1016/S1567-5688(15)50005-6
hcfmusp.relation.referenceFerreira AM, 2017, AM J CARDIOVASC DRUG, V17, P169, DOI 10.1007/s40256-016-0205-0
hcfmusp.relation.referenceFilippatos TD, 2017, EXPERT REV CLIN PHAR, V10, P187, DOI 10.1080/17512433.2017.1263565
hcfmusp.relation.referenceFriedman HS, 2011, CLIN THER, V33, P212, DOI 10.1016/j.clinthera.2011.02.011
hcfmusp.relation.referenceGouni-Berthold I, 2008, CLIN ENDOCRINOL, V68, P536, DOI 10.1111/j.1365-2265.2007.03080.x
hcfmusp.relation.referenceGrosso AF, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-47
hcfmusp.relation.referenceGupta M, 2010, J CARDIOVASC PHARM, V56, P241, DOI 10.1097/FJC.0b013e3181e7fd74
hcfmusp.relation.referenceHernandez-Mijares A, 2016, ATHEROSCLEROSIS, V247, P40, DOI 10.1016/j.atherosclerosis.2016.01.044
hcfmusp.relation.referenceJamaluddin MS, 2012, BRIT J PHARMACOL, V165, P622, DOI 10.1111/j.1476-5381.2011.01369.x
hcfmusp.relation.referenceJoksic J, 2016, CLIN EXP PHARMACOL P, V43, P22, DOI 10.1111/1440-1681.12503
hcfmusp.relation.referenceKhavandi M, 2017, CURR CARDIOL REP, V19, DOI 10.1007/s11886-017-0818-1
hcfmusp.relation.referenceKishimoto Miyako, 2011, J Med Invest, V58, P86, DOI 10.2152/jmi.58.86
hcfmusp.relation.referenceKoh KK, 2015, INT J CARDIOL, V199, P126, DOI 10.1016/j.ijcard.2015.07.016
hcfmusp.relation.referenceKrysiak R, 2012, J INTERN MED, V271, P32, DOI 10.1111/j.1365-2796.2011.02394.x
hcfmusp.relation.referenceKrysiak R, 2015, ENDOKRYNOL POL, V66, P114, DOI 10.5603/EP.2015.0017
hcfmusp.relation.referenceKrysiak R, 2014, CARDIOVASC THER, V32, P40, DOI 10.1111/1755-5922.12057
hcfmusp.relation.referenceLi LL, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0004-7
hcfmusp.relation.referenceLibby P, 2010, J NUCL MED, V51, p33S, DOI 10.2967/jnumed.109.069633
hcfmusp.relation.referenceLivak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
hcfmusp.relation.referenceMinder CM, 2013, CURR OPIN CARDIOL, V28, P554, DOI 10.1097/HCO.0b013e32836429e6
hcfmusp.relation.referenceNakamura K, 2014, J CARDIOL, V63, P250, DOI 10.1016/j.jjcc.2013.11.006
hcfmusp.relation.referenceNaruse R, 2015, OBES RES CLIN PRACT, V9, P67, DOI 10.1016/j.orcp.2014.02.001
hcfmusp.relation.referenceNu baumer B, 2016, DTSCH ARZTEBL INT, V113, P445
hcfmusp.relation.referencePark H, 2011, J GASTROENTEROL, V46, P101, DOI 10.1007/s00535-010-0291-8
hcfmusp.relation.referenceRosen JB, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0075-5
hcfmusp.relation.referenceRotella CM, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-80
hcfmusp.relation.referenceSatoh M, 2015, CLIN SCI, V129, P93, DOI 10.1042/CS20150027
hcfmusp.relation.referenceTakase S, 2017, ARTERIOSCL THROM VAS, V37, P350, DOI 10.1161/ATVBAHA.116.308388
hcfmusp.relation.referenceTamaki N, 2012, J ATHEROSCLER THROMB, V19, P532
hcfmusp.relation.referenceTamura Y, 2012, J ATHEROSCLER THROMB, V19, P608
hcfmusp.relation.referenceTobaru T, 2013, HEART VESSELS, V28, P39, DOI 10.1007/s00380-012-0243-8
hcfmusp.relation.referenceToth PP, 2016, AM J CARDIOL, V118, P1812, DOI 10.1016/j.amjcard.2016.08.071
hcfmusp.relation.referenceTsiotra PC, 2008, MEDIAT INFLAMM, DOI 10.1155/2008/892864
hcfmusp.relation.referenceYu Chih-Chieh, 2012, BMC Res Notes, V5, P251, DOI 10.1186/1756-0500-5-251
hcfmusp.relation.referenceZafrir B, 2014, CARDIOVASC DRUG THER, V28, P361, DOI 10.1007/s10557-014-6534-9
hcfmusp.relation.referenceZinellu A, 2016, J PHARMACEUT BIOMED, V129, P383, DOI 10.1016/j.jpba.2016.07.025
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication417df75f-4506-444e-9eaa-e97b5ee62a9b
relation.isAuthorOfPublicationee44fa3e-4546-4f6c-a73a-539f9d0c16b6
relation.isAuthorOfPublication3cd14016-b7f5-4599-a8b8-45051b7d54b1
relation.isAuthorOfPublication.latestForDiscovery417df75f-4506-444e-9eaa-e97b5ee62a9b
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_GUIMARAES_Effects_of_shortterm_addon_ezetimibe_to_statin_treatment_2017.PDF
Tamanho:
477.4 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - ODS/03